Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 for Intraoperative Imaging of Pulmonary Nodules
NCT04315467Phase 1Completed
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sgm-101 in non-small cell lung cancer (NSCLC). Primary endpoints: Sensitivity of SGM-101 uptake and expression, Specificity of SGM-101 uptake and expression and 1 more. Started Jul 2020; status: completed.
02
Drugs
sgm-101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04315467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315467.